Search

everythinglearnresearchcommunity

for

Search:↓

China approved Sinovac's flu vaccine, Japan approved RiUP for female hair loss, and Nippon Kayaku's three cancer drugs.

A PTH-based treatment improved hair regrowth better than ruxolitinib in a mouse model of hair loss.

Topical Ruxolitinib may safely treat severe hair loss.

The document concluded that certain compounds might strongly bind to and potentially inhibit a key SARS-CoV-2 protein, but further testing is needed.

Rezpegaldesleukin shows promise for treating severe alopecia areata.

Rivaroxaban can cause liver injury, allergic reactions, blood vessel inflammation, and hair loss, but these side effects are rare.

JAK inhibitors help hair growth by boosting beta-catenin activity in hair root cells.

JAK inhibitors show promise for treating hair loss in alopecia areata but need more clinical trials to confirm safety and effectiveness.

JAK inhibitors effectively and safely treat alopecia areata with few serious side effects.

Oral JAK inhibitors show promise for treating alopecia areata but have challenges like relapse and side effects.

Blocking mTORC1 reduces skin tumor growth in mice.

Hit15 shows promise as a COVID-19 treatment by reducing virus infection and inflammation.

Peginterferon alfa-2b and ribavirin therapy for hepatitis C can cause serious side effects, some different from those reported in clinical trials.

JAK inhibitors show promise for treating alopecia areata, but more research is needed.

The framework helps predict adverse effects of blood thinners, improving drug selection for atrial fibrillation.

Upadacitinib may effectively treat resistant lichen planopilaris.

Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.

TAK-279 effectively reduces psoriasis symptoms and is safe.

Nirmatrelvir/Ritonavir treatment may lead to a weaker immune response to COVID-19, but doesn't affect the chance of rebound.

RAPK is a rare skin disorder with pigmented spots, mainly on hands and feet, starting in youth.

Tianeptine may help prevent hair loss by promoting hair growth and reducing cell death.

Nilotinib can cause generalized keratosis pilaris.

Baricitinib effectively treats certain skin conditions but may have serious side effects.

Risankizumab effectively treats and maintains skin clearance in moderate-to-severe psoriasis.

JAK inhibitors, like baricitinib, are effective and safe for treating alopecia areata.

KRDQN effectively predicts adverse drug reactions with high accuracy and clear explanations.

Breast cancer patients taking CDK4/6 inhibitors are more likely to experience fatigue, hair loss, and mouth sores.